Forte Biosciences Inc
FBRX
Company Profile
Business description
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
Contact
3060 Pegasus Park Drive
Building 6
DallasTX75247
USAT: +1 310 618-6994
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
16
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks
ASX share ticks all the popular thematic boxes
The shares are overvalued as investors are overly excited about defence and gold exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,129.60 | 22.10 | -0.24% |
| CAC 40 | 8,347.20 | 0.00 | 0.00% |
| DAX 40 | 25,420.66 | 15.32 | 0.06% |
| Dow JONES (US) | 49,191.99 | 398.21 | -0.80% |
| FTSE 100 | 10,137.35 | 3.35 | -0.03% |
| HKSE | 26,940.41 | 91.94 | 0.34% |
| NASDAQ | 23,709.87 | 24.03 | -0.10% |
| Nikkei 225 | 54,360.87 | 811.71 | 1.52% |
| NZX 50 Index | 13,695.33 | 39.28 | 0.29% |
| S&P 500 | 6,963.74 | 13.53 | -0.19% |
| S&P/ASX 200 | 8,800.30 | 21.50 | -0.24% |
| SSE Composite Index | 4,158.15 | 19.39 | 0.47% |